ASCO 2022 | De-escalation strategies to optimize oncologic control and minimize toxicity

Ari Rosenberg, MD, University of Chicago, Chicago, IL, provides an overview of de-escalation strategies to optimize oncologic control and minimize toxicity, including risk and response adapted de-escalation and replacing cisplatin with other types of regimens. Investigation of methods are usually limited to single-arm Phase II studies and are required to be explored in a randomized setting to be incorporated into standard of care. Dr Rosenburg additionally discusses novel biomarkers for grading treatment response and surveillance. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.